Skip to contentR
Relay Therapeutics, Inc.
R
RLAYRelay Therapeutics, Inc. Q1 2025 · 10-Q
Revenue$7.68M$7.68M−23.3% vs Q1 2024 Net Income-$77.07M-$77.07MN/M vs Q1 2024 EPS Diluted-$0.46-$0.46N/M vs Q1 2024 Operating Income-$84,869,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Relay Therapeutics, Inc. · CIK 1812364 · Engraved from SEC EDGAR
Free Cash Flowderived-$73,594,000N/M Margins · derivedOperating margin-1105.2%−202.2 pt vs Q1 2024
Net margin-1003.6%−190.3 pt vs Q1 2024
ended Mar 31, 2025 · filed May 5, 2025 · 35 d after period end